Business
Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO
SALT LAKE CITY, May 15, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health
About this update from Sera Prognostics, Inc.
[{"type":"text","content":"SALT LAKE CITY, May 15, 2023 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the retirement of the Company's President and CEO, Gregory C. Critchfield, M.D., M.S. Dr. Critchfield is retiring after 12 years of dedicated and valuable service to the Company. Dr. Critchfield plans to step down from his executive role effective June 8, 2023, to pursue other activities. Zhenya Lindgardt, a member of the Company's Board of Directors, will succeed Dr. Critchfield, as Interim CEO & President. Kim Kamdar, Ph.D., a member of the Board, has been appointed as Chair of the Board. Dr. Critchfield continues his service as a member of the Board.\n\n \n \n \n \n \n \n\n \n\"On behalf of Sera Prognostics' Board of Directors, I want to express our deep appreciation for all that Greg has done to lead Sera from its inception to its important role today in protecting mothers and babies with its PreTRM® pregnancy test as well as a pipeline of other potentially ground-breaking pregnancy-related test products,\" said Dr. Kamdar. \"Greg has been a remarkable leader, and we look forward to his continued participation as a member of the Board of Directors. We are also grateful to Zhenya Lindgardt for her forthcoming leadership, and we believe her significant experience in leading high-growth organizations will, for the interim, help shape the Company's strategy and operations in the next exciting phase in the Company's development.\"\n\"Sera is well positioned to be a leading provider of solutions to improve the well-being of mothers and babies with its PreTRM test and other valuable pregnancy predictions in its robust pipeline,\" said Dr. Critchfield. \"With these and other accomplishments in place after 12 years with the Company, this is the right time in Sera's history and development for me to help transfer the leadership of Sera into Zhenya's capable hands to drive Sera's growth to the next level . I am excited to work with Zhenya and the Board as we move forward.\"\n\"At this juncture, given positive AVERT data and the potential for the PRIME data to foster additional volume growth for PreTRM, I am excited to step into an operating leadership role in the Company to support Sera...